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Apo(a)-isoform size, nutritional status and inflammatory markers in
chronic renal failure. Atherosclerotic cardiovascular disease and malnu-
trition are widely recognized as leading causes of the increased morbidity
and mortality observed in uremic patients. Levels of lipoprotein (a)
[Lp(a)], an established cardiovascular risk factor, are elevated in uremic
patients. Moreover, low serum albumin levels indicating malnutrition have
been associated with elevated plasma Lp(a) levels in dialysis patients.
However, serum albumin levels are also influenced by an inflammatory
reaction. The present study was undertaken to further investigate the
relationship between Lp(a), inflammation and malnutrition in patients
with chronic renal failure (CRF) prior to the initiation of renal replace-
ment therapy, and to investigate the potential relation between these
factors and apo(a)-isoform size, an important determinant of plasma
Lp(a) levels. A total of 83 patients (mean age 52 6 1 year) with terminal
(creatinine clearance 9 6 1 ml/min) CRF were cross sectionally investi-
gated. In addition to lipid parameters and apo(a)-isoform size, C-reactive
protein (CRP), nutritional parameters including serum levels of albumin
and body composition (dual energy x-ray absorptiometry), as well as a
subjective global assessment (SGA) and the prevalence of cardiovascular
disease (CVD) were evaluated. Malnourished patients (N 5 39) had a
significantly (P , 0.05) higher median plasma Lp(a) level (19.5 mg/dl) as
compared to 44 well-nourished patients, (11.7 mg/dl). No difference was
found for other lipid or lipoprotein parameters. A significant relationship
was found between CRP and plasma Lp(a), whereas no significant relation
was observed between plasma Lp(a) and serum albumin levels. The
apo(a)-isoform distribution was similar among malnourished and well-
nourished patients. There was no difference in nutritional parameters
when comparing patients with small- and large-size apo(a) isoforms.
However, a subgroup of patients (12%) with no detectable apo(a)-bands
and low Lp(a) levels had significantly higher lean body mass. The present
study demonstrates elevated plasma Lp(a) levels in CRF patients with
signs of malnutrition, even though no direct relationships between plasma
Lp(a) levels and various nutritional parameters were observed. The
observed relationship between Lp(a) and CRP suggests that inflammatory
factors, more prevalent in patients with malnutrition, may contribute to
the Lp(a) increase in malnourished CRF.
Atherosclerotic vascular disease is a major cause of morbidity
and mortality in patients with chronic renal failure (CRF) under-
going renal replacement therapy [1, 2]. The cause(s) may be
multifactorial, although deranged lipoprotein metabolism is con-
sidered to be of importance. Lipoprotein(a) [Lp(a)] is a choles-
terol-rich, LDL-like particle whose protein moiety contains
apo(a) and apo B-100 [3]. A number of epidemiological studies
have shown that Lp(a) is an independent risk factor for athero-
sclerotic complications in uremic [4] as well as in non-uremic
populations [5, 6]. Protein-energy malnutrition with muscle wast-
ing is present in a large proportion of patients with CRF and is, in
addition to atherosclerosis, a strong risk factor for mortality in
patients undergoing HD or CAPD [7]. Interestingly, malnutrition
has also been shown to be associated with increased cardiovascu-
lar mortality in hemodialysis patients [8]. Low serum albumin
concentrations, usually used as an index of malnutrition, are
highly associated with increased mortality risk in patients with
renal replacement therapy [9]. We [10] and others [11] have
previously demonstrated that elevated plasma Lp(a) levels in
CAPD correlate to peritoneal albumin losses. One possible
mechanism may be that hypoalbuminemia causes a reduction in
serum oncotic pressure, stimulating hepatic synthesis of albumin
and other liver-derived proteins including apolipoproteins. In
accordance with this proposal, Yang et al [12] have demonstrated
markedly elevated Lp(a) concentrations only in hemodialysis
patients with low serum albumin levels and Kang et al [13]
recently demonstrated that nutritional status may influence
plasma Lp(a) levels in CAPD patients. Taken together, these
studies suggest that elevated Lp(a) levels are associated with low
serum albumin levels and/or malnutrition in patients with CRF.
However, it has recently been demonstrated that high concentra-
tions of acute-phase proteins, such as CRP, are correlated with
low serum albumin in malnourished hemodialysis patients [14].
Furthermore, recent studies demonstrate that Lp(a) levels in-
crease as a component of the acute phase cascade during inflam-
mation [15–17]. Accordingly, one could speculate that elevated
Lp(a) levels may be a link between inflammation, the nutritional
status and the observed increased cardiovascular mortality in
malnourished patients with CRF.
The present study was undertaken to investigate whether or not
there is an association between nutritional status, serum albumin,
CRP and plasma Lp(a) levels in patients with advanced CRF prior
to the start of renal replacement therapy. In addition, apo(a)
exhibits a genetic size polymorphism that accounts for a major
part of the variation in plasma Lp(a) levels, and we therefore
investigated the association between apo(a)-isoforms, inflamma-
tion and nutritional status, an area previously not addressed
among patients with advanced renal failure.
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METHODS
In this cross sectional study we studied 83 patients (48 males
and 35 females; 58% and 42%, respectively) with chronic renal
failure (CRF) prior to the start of dialysis treatment. Patients .70
years of age were excluded. The clearance of creatinine at the
time-point of examination was 9 6 1 ml/min (range 2 to 19
ml/min). The mean age of the subjects was 52 6 1 years (range 23
to 69 years) and the body-mass index (BMI), defined as the weight
in kilograms divided by the square of the height in meters, was
24.6 6 0.6 kg/m2 (range 14.3 to 41.3 kg/m2). The cause of CRF
was diabetic nephropathy in 25 patients (30%), chronic glomeru-
lonephritis in 28 patients (34%), polycystic kidney disease in 10
patients (12%), interstitial nephritis in 4 patients (5%), nephro-
sclerosis in 2 patients (2%) and other etiologies in 14 patients
(17%). Most patients were on antihypertensive medications [beta-
blockers, calcium channel blockers, furosemide and angiotensin
converting enzyme (ACE)-inhibitors] as well as other commonly
used drugs in terminal CRF such as phosphate and potassium-
binders as well as vitamin B, C and D supplementation. Two of
the patients were on HMG-CoA-reductase inhibitors. Twenty of
the patients (24%) had clinical signs of cardiovascular and/or
peripheral vascular disease (grouped as CVD). Of these 20
patients, seven had suffered from cerebrovascular disease; seven
had one or more myocardial infarctions; seven had clinical signs of
ischemic heart disease (angina pectoris), and four had peripheral
ischemic atherosclerotic vascular disease. At the time of the study
the mean urinary urea excretion was 208 6 10 mmol/24 hr and the
mean urinary albumin excretion 2389 6 296 mg/24 hr (range 52 to
9200 mg/24 hr). The patient group was compared to a group of
healthy subjects (N 5 259) matched for age (52 6 1 year) and
gender (53% males) in which plasma Lp(a) levels were analyzed.
The study protocol was approved by the Ethics Committee of
Karolinska Institute at Huddinge University Hospital, Stockholm
and informed consent was obtained from each patient.
Analyses of blood lipids and apo(a)-phenotypes
The levels of serum serum cholesterol and triglycerides were
analyzed by standard enzymatic procedures (Boehringer Mann-
heim, Mannheim, Germany). High density lipoprotein (HDL)-
cholesterol levels were determined after precipitation of apo
B-containing lipoproteins by phosphotungstic acid [18]. Low
density lipoprotein (LDL)-cholesterol levels were calculated using
the Friedewald formula [19]. Levels of apolipoprotein A-I (apo
A-I) and apo B were determined using an immunonephelometric
procedure (Behring AG, Marburg, Germany). Plasma Lp(a)
levels were analyzed using a two-site immunoradiometric assay
(Pharmacia, Uppsala, Sweden). The method uses two monoclonal
antibodies to different epitopes of apo(a), one labeled with 125I
and one coupled to microsepharose. The coefficient of variation
was 3.8% at a standard concentration of 36.4 mg/dl and 7.2% at a
standard concentration of 13.7 mg/dl. The Lp(a) serum standard
was obtained from Immuno AG (Vienna, Austria). Apo(a)-
phenotyping was performed using Western blotting essentially as
described by Kamboh, Ferrell and Kottke [20]. Briefly, plasma
samples were separated on a 2% submarine agarose gel for 15
hours at 100 V at 4°C. Thereafter, the proteins were blotted onto
a nitrocellulose membrane using an electroblotter for three hours
in the cold. The nitrocellulose membrane was blocked using
powdered skim milk (Carnation) and then incubated with a
primary antibody against apo(a). The apo(a)-bands were visual-
ized with the ECL Amersham technique on Kodak X-OMAT
films using a second, labeled antibody. The results were related to
standards with known apo(a)-isoform sizes, obtained from Im-
muno AG (Innsbruck, Austria). Isoform size was expressed as
number of kringle 4 (K4) repeats. When two apo(a)-isoform sizes
were seen, the intensity of the bands were judged by visual
inspection. In these cases, the band with the highest intensity, that
is, the dominating apo(a)-isoform size, was used in the statistical
analysis.
Analyses of nutritional parameters
Subjective global nutritional assessment (SGA) was used to
evaluate the overall protein-energy nutritional status [21, 22].
SGA includes six subjective assessments, three based on the
patient’s history of weight loss, incidence of anorexia and inci-
dence of vomiting, and three based on the subjective grading of
muscle wasting, presence of edema and loss of subcutaneous fat.
Based on these assessments each patient was given a score which
reflects the nutritional status as follows: 1 5 normal nutritional
status, 2 5 mild malnutrition, 3 5 moderate malnutrition and 4 5
severe malnutrition. Determinations of serum albumin (bro-
mecresol purple), C-reactive protein (CRP), serum creatinine,
urinary albumin, urinary creatinine and urinary urea excretion
were performed by routine procedures in the Department of
Clinical Chemistry, Huddinge Hospital. The detection limit of
CRP was 10 mg/liter, and all values , 10 mg/liter were in the
statistical evaluation treated as 9 mg/liter. Body composition was
evaluated by dual-energy x-ray absorptiometry (DXA; Lunar
Corp., Madison, WI, USA) with Lunar software version 3.4.
Complete data on body composition were missing in 9 of the
patients.
Statistical analyses
Data are presented as mean 6 SEM with P , 0.05 taken to
indicate a significant difference. The non-parametric Mann-Whit-
ney U-test was used to compare differences between the groups.
Comparisons between two groups for nominal variables were
made by Fisher’s exact test. Correlations were performed by linear
regression analysis. However, as plasma Lp(a) was not normally
distributed, correlations between Lp(a) and other variables were
performed with the Spearman rank test.
RESULTS
Plasma Lp(a) levels were significantly (P 5 0.0002) elevated in
83 patients with CRF (median 14.3 mg/dl; range 1.2 to 147.0
mg/dl) as compared to 259 healthy subjects (median 6.9 mg/dl;
range 1.2 to 121.1 mg/dl). The cumulative incidence of Lp(a)
levels in the two groups are shown in Figure 1. The patients were
divided into two groups based on nutritional assessment by SGA
(Table 1). Forty-four patients (53%) had a normal nutritional
status (SGA 1) whereas 39 patients (47%) had signs of mild or
moderate malnutrition (SGA 2-3). No patient had sign of severe
malnutrition (SGA 4). As seen in Table 1, the mean age of the
patients in the malnourished group was significantly higher (57 6
2 vs. 47 6 2 years; P , 0.001) as compared to the SGA 1 group.
In the well-nourished group (SGA 1) 30 of the patients were men
(68%), whereas 46% (N 5 18) were men in the malnourished
group (SGA 2-3) of patients. Cardiovascular disease was signifi-
cantly more prevalent among patients with SGA 2-3 (P , 0.001).
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Whereas no significant differences were seen between the two
groups in serum cholesterol, triglycerides, HDL cholesterol, LDL
cholesterol, apoA-I or apoB levels, a significant increase in
median Lp(a) levels (19.5 vs. 11.7 mg/dl; P , 0.05) was observed
in the malnourished group (SGA 2-3) of patients.
The nutritional parameters in the two groups of patients are
shown in Table 2. Compared to the well-nourished group (SGA
1), body wt was significantly lower in the malnourished group
(SGA 2-3, 69 6 3 vs. 77 6 2 kg; P , 0.01) as were serum albumin
levels (31 6 1 vs. 34 6 1 g/liter; P , 0.05), while CRP levels were
higher (25 6 4 vs. 13 6 3 mg/liter; P , 0.01). The 24-hour urinary
urea excretion was significantly lower (180 6 14 vs. 229 6 13
mmol/24 hr; P , 0.05) in the malnourished group. In contrast,
there was no difference in the 24-hour urinary albumin excretion
between the malnourished (2273 6 454 mg/24 hr) and well-
nourished (2477 6 402 mg/24 hr) patient groups. No significant
correlations were observed between plasma Lp(a) levels and
serum albumin, 24-hour urinary albumin excretion or any other
nutritional parameter. However, a significantly positive correla-
tion (Rho 5 0.23; P , 0.05) was observed between plasma CRP
and Lp(a) levels. Moreover, a positive significant correlation was
observed between age and CRP levels (r 5 0.32; P , 0.01). As
expected, body composition analysis by DXA revealed a signifi-
cantly (P , 0.0001) lower lean body mass (44.0 6 1.4 kg) in the
malnourished group compared to the well-nourished group
(54.3 6 1.6 kg), whereas no significant difference in the amount of
body fat was seen. A weak, but significant (Rho 5 0.24; P , 0.05),
correlation was observed between Lp(a) and relative body fat
mass (%), whereas no significant correlation was observed be-
tween Lp(a) versus total body fat mass (kg).
The median apo(a)-isoform size was 29 kringle 4 (K4)-units. Of
the 83 patients, 64 had a pattern where one apo(a)-isoform clearly
dominated. In nine patients, both isoforms were quantitatively
comparable: three patients had both isoforms , 29 K4 units, three
had both isoforms . 29 K4 units, and in three patients one
isoform was . 29 K4 units and one isoform , 29 K4 units. For
these three latter patients, the mean isoform size was used. All in
all, 39 of the patients (47%) had either a dominating or two
high-molecular weight apo(a)-isoforms (defined as $ 29 K4;
HMW), whereas 34 patients (41%) had a dominating or two
low-molecular-weight apo(a)-isoforms (, 29 K4 units; LMW). In
ten of the patients (12%), we could not detect any apo(a)-isoform
bands by immunoblotting. An inverse correlation (Rho 5 20.45;
P 5 0.0002) was observed between plasma Lp(a) levels and the
molecular size of the dominating apo(a)-isoform in the patients
with detectable isoforms as shown in Figure 2. The mean age was
51 6 2 years in the HMW-isoform group and 55 6 2 years in the
LMW-isoform group, which was significantly (P , 0.05) higher
than the age in the patient group without detectable apo(a)-bands
(43 6 4 years). However, age did not correlate to any of the lipid
parameters or apo(a)-isoforms.
Lipid parameters in the three apo(a)-phenotype groups
(HMW, LMW and no bands) are shown in Table 3. No significant
differences with respect to serum cholesterol, triglycerides, high
density lipoprotein (HDL)-cholesterol, low density lipoprotein
(LDL)-cholesterol, apoA-I or apoB levels were observed. How-
ever, as expected, the median plasma Lp(a) levels were signifi-
cantly higher in the LMW group (29.6 mg/dl; P , 0.001) and
HMW group (14.3 mg/dl; P , 0.001) as compared to the group of
patients with no detectable apo(a)-bands (1.2 mg/dl), respectively.
Moreover, no significant differences with respect to either gender
or number of patients with diabetes mellitus were demonstrated
between the three groups.
Fig. 1. Cumulative frequency distribution curves of Lp(a) concentrations
in 259 healthy control subjects (M) and 83 patients with chronic renal
failure (E).
Table 1. Clinical and lipid parameters in 83 CRF patients with no signs
of malnutrition (SGA 1) and moderate to severe (SGA 2-3)
malnutrition
Normal nutrition
(SGA 1)
Malnutrition
(SGA 2-3) Significance
Number 44 39
Age years 47 6 2 57 6 2 P , 0.001
Gender (M/F) 30/14 18/21 NS
Prevalence of CVD % 7% 44% P , 0.001
CRP mg/liter 13 6 3 25 6 4 P , 0.001
Serum cholesterol mmol/liter 6.0 6 0.2 6.1 6 0.3 NS
Triglycerides mmol/liter 2.5 6 0.2 2.3 6 0.2 NS
HDL cholesterol mmol/liter 1.2 6 0.1 1.3 6 0.1 NS
LDL cholesterol mmol/liter 3.7 6 0.2 3.5 6 0.2 NS
ApoB g/liter 1.23 6 0.05 1.26 6 0.07 NS
ApoA-1 g/liter 1.41 6 0.07 1.40 6 0.07 NS
Lp(a) mg/dla 11.7 (1.2-102.9) 19.5 (1.3-147.0) P , 0.05
Data are mean 6 SEM. Abbreviations are: CRF, chronic renal failure;
CVD, cardiovascular disease; CRP, C-reactive protein; HDL, high density
lipoprotein; LDL, low density lipoprotein; SGA, subjective global assess-
ment.
NS, not significant.
a Median and range
Table 2. Comparisons of various nutritional parameters in 83 chronic
renal failure patients with no signs of malnutrition (SGA 1) and
moderate to severe (SGA 2-3) malnutrition
Normal nutrition
(SGA 1)
Malnutrition
(SGA 2-3) Significance
Number 44 39
Weight kg 77 6 2 69 6 3 P , 0.01
Serum albumin g/liter 34 6 1 31 6 1 P , 0.05
Urine Urea mmol/24 hr 229 6 13 180 6 14 P , 0.05
Body fat mass % 27.8 6 1.3a 32.1 6 2.0a NS
Body fat mass kg 21.9 6 1.4a 22.4 6 2.3a NS
Lean body mass kg 54.3 6 1.6a 44.0 6 1.4a P , 0.0001
Data are mean 6 SEM. NS is not significant.
a N 5 37
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No significant differences were observed in any of the nutri-
tional parameters between the HMW- and LMW-isoform groups,
respectively (Table 4). Of the 73 patients with detectable isoforms,
one half (N 5 36) were well-nourished and belonged to the SGA
1 group, and one half (N 5 37) showed signs of malnutrition and
were classified as SGA 2-3. In the latter, the malnourished group,
half of the patients (N 5 19) had a dominating isoform size , 29
K4 units, while 18 patients had a dominating apo(a)-size $ 29 K4
units. Of the 36 patients in the well-nourished group (SGA 1), the
larger apo(a)-isoform sizes ($ 29 K4 units) were somewhat more
common (N 5 21). However, the overall pattern of distribution
between LMW and HMW apo(a)-sizes did not differ to any large
extent between the two nutrition groups. In the group of patients
without detectable apo(a)-bands, body weight and serum albumin
levels did not differ, whereas the amount of relative body fat was
significantly lower as compared to the groups of patients with
LMW and HMW apo(a) phenotypes, respectively. Moreover, the
lean body mass in the group of patients with no detectable
apo(a)-bands was markedly higher (P , 0.05) as compared to
both the HMW and LMW apo(a)-phenotype groups of patients,
respectively. As seen in Table 4, eight of the 10 patients with no
detectable apo(a) bands belonged to the SGA 1 group.
To compare the impact of age and gender on the observed
differences on body fat mass and lean body mass, subgroup
analyses were performed. When the group of patients with no
detectable apo(a)-bands were compared to a group of patients
(N 5 34) with detectable apo(a)-bands matched for age (42 6 2
years), the significant differences in both body fat mass (29.9 6 1.7
vs. 22.2 6 2.4%; P , 0.05) and lean body mass (56.5 6 2.9 vs.
48.0 6 2.0 kg; P , 0.05) persisted. Moreover, a subgroup analysis
with respect to gender revealed that the seven men with no
detectable apo(a)-bands had significantly (P , 0.01) lower body
fat mass (20.0 6 2.6 vs. 31.6 6 2.3 and 27.1 6 1.9%) and
significantly (P , 0.05) higher lean body mass (61.2 6 1.9 vs.
46.4 6 2.4 and 55.0 6 1.8 kg) compared to 21 men with HMW and
20 men with LMW apo(a) phenotypes, respectively. No significant
differences in body fat mass or lean body mass were obtained in
the three apo(a)-phenotype groups among the women.
DISCUSSION
It is well known, and also confirmed in the present study, that
Lp(a) levels are higher among CRF subjects. An additional
important finding in the present study was that Lp(a) levels were
even higher among CRF patients with signs of malnutrition and
inflammation. Apo(a), the unique protein in Lp(a), has a complex
genetic regulation, and the apo(a)-isoform pattern influences
plasma Lp(a) levels to a high degree. To the best of our
knowledge, apo(a)-isoform size has previously not been investi-
gated in relation to nutritional parameters in CRF. In our study,
we demonstrate that the apo(a)-isoform pattern does not influ-
ence the relationship between Lp(a) and the inflammatory reac-
tion and nutritional status in CRF patients. However, the rela-
tionship between subjective global assessment and Lp(a) was to a
large extent related to differences in inflammatory reaction be-
tween these groups of patients. These findings suggest that
inflammatory and/or nutritional status influences Lp(a) levels in
CRF patients over and above the major genetic factors that under
normal conditions regulate plasma Lp(a) levels.
Plasma Lp(a) is a cholesterol-rich, LDL-like particle, whose
protein moiety contains apo(a) in addition to apoB-100 [3]. Apo
B-100 is present also in other lipoproteins, but apo(a) is unique to
Lp(a). High plasma concentrations of Lp(a) are associated with
risk of premature coronary atherosclerosis and other vascular
diseases in hemodialysis patients [4]. In the present study, signif-
icantly elevated plasma Lp(a) levels were found in CRF patients
prior to the initiation of renal replacement therapy (Fig. 1),
confirming previous results [23]. This suggests that uremia, by
unknown mechanisms, causes an increase in Lp(a) levels. In
normal subjects, the genetic size polymorphism of apo(a) explains
a major part (about 45 to 70%) of the variability of plasma Lp(a)
[24]. Also among the present patients with CRF, there was a
strong inverse correlation between apo(a)-isoform size and
plasma Lp(a) concentration (Fig. 2). This finding was particularly
striking when using the present high-resolution technique, allow-
ing for detection of more than 30 different isoform sizes. This
inverse relationship suggests that the influence of isoform-size
variation on plasma Lp(a) levels is also important in renal failure,
and gives further support to the idea that uremic effects on Lp(a)
are superimposed on basic regulatory mechanisms. As well, this
concept is in agreement with the finding that the overall apo(a)-
isoform frequency did not vary between renal patients and healthy
controls [25]. However, as can be seen in Figure 2, there were
some notable exceptions to the general inverse relation between
apo(a) size and plasma Lp(a) levels. Several patients with low
molecular weight isoforms displayed low plasma Lp(a) levels,
suggesting that other factor(s) apart from apo(a)-isoform size
influenced Lp(a) levels. The importance of variation in the
apo(a)-gene apart from number of K4 repeats for plasma Lp(a)
levels was recently underscored by the finding that a polymor-
phism in the non-coding part of the gene affected plasma Lp(a)
levels differently depending on ethnicity [26]. Whether such
genetic variations may influence plasma Lp(a) levels in these
subjects remains to be shown.
As the increase in Lp(a) in CRF subjects has not been
explained by genetic factors to date, it seems likely that it could be
due to gross albuminuria, decreased glomerular filtration rate
(GFR), inflammation or the renal replacement therapy per se. It
has previously been demonstrated that especially among patients
Fig. 2. The relationship (Rho 5 20.45; P < 0.0002) between isoform size
(K4) and plasma Lp(a) levels in 73 patients with chronic renal failure and
detectable apo(a)-isoforms. Symbol (M) represents patients with low
plasma Lp(a) levels in relation to their apo(a)-isoform size.
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with significant losses of albumin, such as patients with nephrotic
syndrome [27, 28] or patients treated by CAPD [10, 11], plasma
Lp(a) levels are markedly elevated. As it has been proposed that
hypoalbuminemia stimulates the hepatic production of lipopro-
teins [29], elevated plasma Lp(a) levels in nephrotic syndrome and
in CAPD patients might at least be partly explained by hepatic
overproduction of Lp(a). Indeed, we recently demonstrated that
elevated LDL-apoB production is highly correlated to the prevail-
ing serum albumin levels in patients with nephrotic syndrome [30].
However, Lp(a) metabolism is complex and the detailed mecha-
nisms have still not been clarified. Hence, it remains to be shown
whether hepatic overproduction of apoB or apo(a), or alterna-
tively Lp(a), or increased formation of Lp(a) in the circulation
occurs in CRF patients and could contribute to the increased
levels. Alternatively, the decreased renal function may impact on
Lp(a) clearance, although currently no information is available on
Lp(a) clearance pathways. In the present study, patients with
markedly decreased GFR and moderate albuminuria were stud-
ied before the initiation of renal replacement therapy. Although
some of the patients in our study had “nephrotic-range” albumin-
uria (. 3000 mg/24 hr), most patients had only minor urinary
albumin losses, and it is therefore unlikely that urinary albumin
losses could be the main cause of elevated plasma Lp(a) levels in
our group of CRF patients. Thus, the most likely cause of the
elevated plasma Lp(a) levels in the present study is renal dysfunc-
tion, in agreement with the markedly reduced GFR. This is also
consistent with the decrease in Lp(a) levels following normaliza-
tion of renal function after renal transplantation [31].
In the present study, 47% of the patients had signs of mild to
moderate malnutrition, a similar prevalence of malnutrition as
previously reported in CRF [32]. As expected, the malnourished
group of patients were older and had significantly poorer nutri-
tional indices, such as lower serum albumin levels, 24-hour urine
urea excretion, and lean body mass (as assessed by DXA). An
important finding in our study was that the plasma Lp(a) concen-
tration was slightly, but significantly, higher in the malnourished
group. This relationship to a large extent was explained by
differences in CRP levels. This result indicates that in CRF, where
Lp(a) levels already are higher than in normals, plasma Lp(a)
levels can be further modulated depending on inflammatory
and/or nutritional parameters. This finding is also in agreement
with a previous cross-sectional study in CAPD patients by Kang et
al [13], who reported on higher Lp(a) levels in malnourished
patients. Unfortunately, CRP or other inflammatory markers
were not reported in their study.
Importantly, there were only minor differences in apo(a)-
isoform distribution pattern between the well-nourished and the
malnourished groups. This suggests that factors other than the
genetically determined apo(a)-isoform size, a major determinant
of plasma Lp(a) levels in normals, resulted in the increase in
Lp(a) levels in the malnourished group of patients. There are
several possible mechanisms that could contribute to this increase.
At first, the malnourished patients in the present study had
significantly elevated C-reactive protein (CRP) levels compatible
with an ongoing infection or inflammation. High CRP levels have
also been seen in hemodialysis patients with signs of malnutrition
[33]. Furthermore, it has recently been demonstrated that high
concentrations of acute-phase proteins, such as CRP, are corre-
lated with low serum albumin levels in hemodialysis patients [14].
In the present study a significantly positive correlation was
observed between CRP and plasma Lp(a) levels, and it has been
suggested that plasma Lp(a) may act as an acute phase protein
[15, 34]. Our data indicate that the elevated Lp(a) levels in the
malnourished CRF patients are, at least partly, caused by an
inflammatory response. Indeed, it has recently been reported that
elevated Lp(a) levels in chronic hemodialysis patients are closely
related to the acute phase reaction [16, 17, 35]. Overall these
results suggest that an increase in hepatic synthesis of apo(a) due
to an acute phase-mediated response could be contributory to the
elevated Lp(a) levels in malnourished CRF patients. It is note-
worthy that cardiovascular disease was significantly more promi-
nent in the SGA 2-3 group, in agreement with a recent study in a
cohort of hemodialysis patients [33]. Interestingly, as seen in
Table 1, of all established lipid risk factors for cardiovascular
disease, only Lp(a) levels were increased in this group. This
finding seem to support the concept that an acute phase response,
as a result of inflammatory disease, increased Lp(a) levels which
Table 3. Lipid parameters in 83 chronic renal failure patients without
detectable apo(a)-bands and high (HMW) and low (LMW) molecular
weight isoforms
No detectable
apo(a)-bands
HMW-isoforms
($ 29 K4)
LMW-isoforms
(, 29 K4)
Number 10 39 34
Serum cholesterol
mmol/liter
5.5 6 0.6 5.9 6 0.3 6.1 6 0.2
Triglycerides
mmol/liter
2.8 6 0.4 2.3 6 0.2 2.4 6 0.2
HDL cholesterol
mmol/liter
1.0 6 0.1 1.3 6 0.1 1.3 6 0.1
LDL cholesterol
mmol/liter
3.4 6 0.6 3.5 6 0.2 3.9 6 0.2
ApoB g/liter 1.21 6 0.15 1.23 6 0.07 1.24 6 0.05
ApoA g/liter 1.32 6 0.11 1.42 6 0.08 1.40 6 0.07
Lp(a) mg/dla 1.2 (1.2-4.3) 14.3 (1.2-70.0)b 29.6 (2.9-147.0)b
Mean 6 SEM are indicated. Abbreviations are: HDL, high density
lipoprotein; LDL, low density lipoprotein.
a Median and range
b P ,0.001 vs. no detectable apo(a)-bands
Table 4. Nutritional parameters and CRP in 83 CRF patients without
detectable apo(a)-bands and high (HMW) and low (LMW) molecular
weight isoforms
No detectable
apo(a)-bands
HMW isoforms
($ 29 K4)
LMW isoforms
(, 29 K4)
Number 10 39 34
Weight kg 75 6 4 72 6 3 74 6 3
Prevalence men % 70% 51% 62%
Prevalence diabetes
mellitus %
30% 26% 35%
CRP mg/liter 15 6 8 15 6 3 18 6 4
Serum albumin g/liter 32 6 2 32 6 1 34 6 1
Body fat mass % 22.2 6 2.4 31.9 6 1.9c,d 30.8 6 2.9b,e
Body fat mass kg 16.4 6 2.1 23.6 6 2.1a,d 22.6 6 2.0e
Lean body mass kg 56.4 6 2.9 46.7 6 1.7b,d 48.9 6 1.9b,e
Prevalence malnutrition
(SGA 2-3)
20% 46% 56%
Mean 6 SEM are indicated. Abbreviations are: CRF, chronic renal
failure; CRP, C-reactive protein; SGA, subjective global assessment.
dN 5 34
e N 5 30
a P 5 0.06, b P , 0.05 and c P , 0.01 vs. no apo(a)-bands
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may contribute to accelerated atherosclerosis in malnourished
patients with CRF. Prospective studies addressing this issue are
clearly needed.
Another possible mechanism for increased Lp(a) levels in the
malnourished CRF patients is that increased urinary losses of
albumin, as in the nephrotic syndrome, cause hypoalbuminemia.
However, even though the malnourished patients had slightly
lower serum albumin levels as compared to the well-nourished
patients, no correlation was observed between plasma Lp(a) and
serum albumin. Moreover, well-nourished and malnourished
CRF patients had similar 24-hour urinary albumin excretion rates,
suggesting that urinary albumin losses do not mediate the increase
in plasma Lp(a) levels in the malnourished group of patients.
Finally, the absence of detectable apo(a)-bands on immunoblot
analysis could have contributed to lower plasma Lp(a) levels in
the well-nourished group of CRF patients. In our study 12% of
the patients had no detectable apo(a)-bands, which is similar to
the prevalence previously reported in the general population [36].
A novel finding in the present study is the association between
absence of apo(a)-bands and nutritional status in patients with
CRF. Our results demonstrate that patients with no detectable
apo(a)-bands, despite a similar body weights, have a substantially
lower body fat mass and higher lean body mass as compared to
CRF patients with detectable apo(a)-bands, representing either
LMW or HMW isoforms. Further prospective studies are clearly
needed to study the long-term prognosis of this subgroup of
patients.
In conclusion, the present study has demonstrated markedly
elevated plasma Lp(a) levels in patients with advanced CRF. The
increase in Lp(a) levels among patients with substantially worse
nutritional status was not related to the apo(a)-isoform size
variation. The observed significant relationship between Lp(a)
and CRP suggests that inflammatory factors, which are more
prevalent in patients with malnutrition, may contribute to the
increase of Lp(a) in CRF and this merits further investigation.
ACKNOWLEDGMENTS
This study was supported by a grant from the Baxter Extramural Grant
Program (P.S.) and a grant-in-aid from the American Heart Association,
New York City Affiliate. Dr. Berglund is an Established Scientist of the
American Heart Association, New York City Affiliate. Dr. Tuck is a
GCRC-funded Clinical Associate Physician (2 M01 RR 00645). We
acknowledge the skilled technical assistance of Ms. I. Sjo¨din, Ms. A. Lif,
Ms. B. Johansson, Ms. M. Ahlberg, Mr. J. Jones, Mr. N. Fontanez and Dr.
A.R. Qureshi.
Reprint requests to Peter Stenvinkel, M.D., Ph.D., Department of Renal
Medicine K56, Huddinge University Hospital, 141 86 Huddinge, Sweden.
E-mail: peter.stenvinkel@klinvet.ki.se
REFERENCES
1. LINDNER A, CHARRA B, SHERRARD DJ, SCHRIBNER BH: Accelerated
atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med
290:697–701, 1974
2. MA KW, GREENE EL, RAIJ L: Cardiovascular risk factors in chronic
renal failure and hemodialysis populations. Am J Kidney Dis 19:505–
513, 1992
3. UTERMANN G, WEBER W: Protein composition of Lp(a) lipoprotein
from human plasma. FEBS Lett 154:357–361, 1983
4. CRESSMAN MD, HEYKA RJ, PAGANINI EP, O’NEIL J, SKIBINSKI CI,
HOFF HF: Lipoprotein(a) is an independent risk factor for cardiovas-
cular disease in hemodialysis patients. Circulation 86:475–482, 1992
5. ARMSTRONG VW, CREMER P, EBERLE E, MANKE A, SCHULZE F,
WIELAND H, KREUZER H, SEIDEL D: The association between serum
Lp(a) concentrations and angiographically assessed coronary athero-
sclerosis: Dependence on serum LDL levels. Atherosclerosis 62:249–
257, 1986
6. DURRINGTON PN, ISHOLA M, HUNT L, ARROL S, BHATNAGER D:
Apolipoprotein (a), A1 and B and parenteral history in men with early
onset ischaemic heart disease. Lancet 1:1070–1073, 1988
7. BERGSTRO¨M J, LINDHOLM B: Nutrition and adequacy of dialysis. How
do hemodialysis and CAPD compare? Kidney Int 34(Suppl 40):S39–
S50, 1993
8. KEANE WF, COLLINS AJ: Influence of co-morbidity on mortality and
morbidity of hemodialysis patients. Am J Kidney Dis 24:1010–1018, 1994
9. LOWRIE EG, LEW NL: Death risk in hemodialysis patients: The
predicitive value of commonly measured variables and an evaluation
of death rate differences between facilities. Am J Kidney Dis 15:458–
482, 1990
10. HEIMBU¨RGER O, STENVINKEL P, BERGLUND L, TRANAEUS A, LIND-
HOLM B: Increased plasma lipoprotein(a) in continuous ambulatory
peritoneal dialysis is related to peritoneal transport of proteins and
glucose. Nephron 72:135–144, 1996
11. WANNER C, BARTENS W, WALZ G, NAUCK M, SCHOLLMEYER P:
Protein loss and genetic polymorphism of apolipoprotein(a) modulate
serum lipoprotein(a) in CAPD patients. Nephrol Dial Transplant
10:75–81, 1995
12. YANG WS, KIM SB, MIN WK, PARK S, LEE MS, PARK JS: Atherogenic
lipid profile and lipoprotein(a) in relation to serum albumin in
haemodialysis patients. Nephrol Dial Transplant 10:1668–1671, 1994
13. KANG DH, YOON KI, LEE SW, KANG SW, CHOI KH, LEE HY, HAN
DS: Impact of nutritional status on serum lipoprotein(a) concentra-
tions in patients undergoing continuous ambulatory peritoneal dialy-
sis. Perit Dial Int 16(Suppl 1):S241–S245, 1996
14. KAYSEN GA, STEVENSON FT, DEPNER TA: Determinants of albumin
concentration in hemodialysis patients. Am J Kidney Dis 29:658–668,
1997
15. NOMA A, ABE A, MAEDA S, SEISHIMA M, MAKINO K, YANO Y,
SHIMOKAWA K: Lp(a): An acute phase reactant? Chem Phys Lipids
67–68:411–417, 1994
16. KARIO K, MATSUO T, KOBAYASHI H, MATSUO M, ASADA R, KOIDE M:
High lipoprotein(a) levels in chronic hemodialysis patients are closely
related to acute phase reaction. Thromb Haemost 74:1020–1024, 1995
17. ZIMMERMAN J, HERRLINGER S, PRUY A, WANNER C: Mechanism of
high serum lipoprotein(a) in hemodialysis patients. (abstract) J Am
Soc Nephrol 8:260A, 1997
18. LOPES-VIRELIA MF, STONE P, ELNIS S, COLWEH JA: Cholesterol
determination in high-density lipoproteins separated by three differ-
ent methods. Clin Chem 23:882–884, 1977
19. FRIEDEWALD WT, LEVY RI, FREDRICKSON DS: Estimation of the
concentration of low-density lipoprotein cholesterol in plasma without
use of the preparative ultracentrifuge. Clin Chem 18:499–502, 1977
20. KAMBOH MI, FERRELL RE, KOTTKE BA: Expressed hypervariable poly-
morphism of apolipoprotein (a). Am J Hum Genet 49:1063–1074, 1991
21. BAKER JP, DETSKY AS, WESSON DE, WOLMAN SL, STEWART S,
WHITEWELL J, LANGER B, JEEJEEBHOY KN: Nutritional assessment: A
comparison of clinical judgment and objective measurements. N Engl
J Med 306:969–972, 1982
22. DETSKY AS, MCLAUGHLIN JR, BAKER JP, JOHNSTON N, WHITTAKER S,
MENDELSON RA, JEEJEEBHOY KN: What is subjective global assess-
ment of nutritional status? J Parenter Enterol Nutr 33:650–653, 1987
23. ARNADOTTIR M, THYSELL H, NILSSON-EHLE P: Serum lipoprotein(a)
is increased in moderate renal failure. Nephron 72:712–713, 1996
24. UTERMANN G, MENZEL HJ, KRAFT HG, DUBA HC, KEMMLER HG, SEITZ
C: Lp(a) glycoprotein phenotypes; inheritance and relation to Lp(a)-
lipoprotein concentrations in plasma. J Clin Invest 80:458–465, 1987
25. KRONENBERG F, KO¨NIG P, NEYER U, AUINGER M, PRIBASNIG A, LANG
U, REITINGER J, PINTER G, UTERMANN G: Multicenter study of
lipoprotein(a) and apolipoprotein(a) phenotypes in patients with
end-stage renal disease treated by hemodialysis or continuous ambu-
latory dialysis. J Am Soc Nephrol 6:110–120, 1995
26. TROMMSDORF M, KO¨CHL S, LINGENHEL A, KRONENBERG F, DELPORT
R, VERMAAK H, LEMMING L, KLAUSEN IC, GAERGEMAN O, UTER-
MANN G, KRAFT H-G: A pentanucleotide repeat polymorphism in the
59 control region of the apolipoprotein(a) gene is associated with
lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest
96:150–157, 1995
Stenvinkel et al: Inflammation and Lp(a) in CRF 1341
27. STENVINKEL P, BERGLUND L, HEIMBU¨RGER O, PETTERSSON E, ALVES-
TRAND A: Lipoprotein(a) in nephrotic syndrome. Kidney Int 44:1116–
1123, 1993
28. WANNER C, RADER D, BARTENS W, KRA¨MER J, BREWER B, SCHOLLM-
EYER P, WIELAND H: Elevated plasma lipoprotein(a) in patients with
the nephrotic syndrome. Ann Intern Med 119:263–269, 1993
29. APPEL GB, BLUM CB, CHIEN S, KUNIS CL, APPEL AS: The hyperlip-
idemia of the nephrotic syndrome: Relation to plasma albumin
concentration, oncotic pressure and viscocity. N Engl J Med 312:1544–
1548, 1985
30. STENVINKEL P, BERGLUND L, ERICSSON S, ALVESTRAND A, ANGELIN
B, ERIKSSON M: Low-density lipoprotein metabolism and its associa-
tion to plasma lipoprotein(a) in the nephrotic syndrome. Europ J Clin
Invest 27:169–177, 1997
31. KRONENBERG F, KO¨NIG P, LHOTTA K, O¨FNER K, SANDHOLZER C,
MARGREITER R, DOSCH E, UTERMAN G, DIEPLINGER H: Apolipopro-
tein(a) phenotype-associated decrease in lipoprotein(a) plasma con-
centrations after renal transplantation. Arteriscler Thromb 14:1399–
1404, 1994
32. KOPPLE JD: Nutritional managment of nondialyzed patients with
chronic renal failure, in Nutritional Managment of Renal Disease,
edited by KOPPLE JD, MASSRY SG, Baltimore, William & Wilkins,
1996, pp 479–531
33. QURESHI AR, ALVESTRAND A, DANIELSSON A, DIVINO-FILHO JC,
GUTIERREZ A, LINDHOLM B, BERGSTRO¨M J: Factors predicting mal-
nutrition in hemodialysis patients. A cross-sectional study. Kidney Int
53:773–782, 1998
34. MAEDA S, ABE A, SESHIMA M, MAKINO K, NOMA A, KAWEDE M:
Transient changes of serum lipoprotein (a) as an acute phase protein.
Atherosclerosis 78:145–150, 1989
35. ZIMMERMAN J, PRUY A, HERRLINGER S, WANNER C: The atherogenic
risk in hemodialysis patients is enhanced by inflammation. (abstract)
J Am Soc Nephrol 8:215A, 1997
36. GAW A, BOERWINKLE E, COHEN JC, HOBBS HH: Comparative analysis
of the apo(a) gene, apo(a) glycoprotein and plasma concentrations of
Lp(a) in three ethnic groups. Evidence for no common “null” allele in
the apo(a) locus. J Clin Invest 93:2526–2534, 1994
Stenvinkel et al: Inflammation and Lp(a) in CRF1342
